The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Novartis Pharmaceuticals Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (11)
- 2024 (20)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Sponsor content
548 result(s) found, displaying 101 to 110
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Kesimpta-Ofatumumab 20 mg/0.4mL solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VSIQQ brolucizumab (rbe) 120 mg/mL solution for injection in vial.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
HYCAMTIN topotecan (as hydrochloride) 1 mg hard capsules Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd -
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENERZAIR BREEZHALER 114/46/136 indacaterol/glycopyrronium/mometasone furoate 114/46/136 microgram powder for inhalation in capsule with inhaler.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENERZAIR BREEZHALER 114/46/68 indacaterol/glycopyrronium/mometasone furoate 114/46/68 microgram powder for inhalation in capsule with inhaler.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd